Lenalidomide Stada Nordic

Lenalidomide, the active ingredient in Lenalidomide Stada Nordic, is an immunomodulatory agent (IMiD) presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Stada Nordic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Lenalidomide is indicated for several hematologic malignancies and works within the immunomodulatory drug class to control disease progression.

Multiple Myeloma: improves progression‑free survival and overall response rates. Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and cytopenias. Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory settings.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Thrombocytopenia: lowered platelet levels, may cause bleeding. - Anemia: decreased red blood cells, leading to fatigue. - Fatigue: general tiredness and weakness. - Nausea: upset stomach, sometimes with vomiting. - Diarrhea: loose stools, occasionally leading to dehydration.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression, high infection risk. - Serious infections: opportunistic or bacterial infections requiring hospitalization. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Monitor blood counts: perform regular CBCs to detect cytopenias. Assess thromboembolic risk: consider prophylactic anticoagulation when risk is high. Avoid pregnancy: enforce strict contraception for both patients and partners. Adjust for renal impairment: dose modifications may be required based on creatinine clearance. Use contraception: both male and female patients must use effective methods. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - P‑glycoprotein substrates (e.g., digoxin): potential for altered plasma levels. - Other immunomodulatory agents (e.g., thalidomide): additive risk of thrombosis. - Vaccines: live vaccines should be avoided due to immunosuppression.